Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recipharm to acquire Hospira subsidiary

This article was originally published in Scrip

Recipharm is to acquire a subsidiary of Hospira, Wasserburger Arzneimittelwerk, for an undisclosed sum.

The contract manufacturing organisation, which is based in Wasserburg, Germany, is focused on aseptic filling and lyophilsation of pharmaceuticals into ampoules and vials on behalf of customers.

The acquisition is part of Recipharm's goal of becoming a leading contract development and manufacturing organisation by offering a 'one-stop shop' for the development and manufacture of large and small-molecule biopharmaceuticals, the company said.

The Swedish firm plans to continue Wasserburger's current operations and retain all of its employees.

Recipharm moved to acquire the UK contract manufacturer of biological Cobra Biomanufacturing last month, valuing the company at £1 million (scripnews.com, December 18th, 2009).

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC006616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel